Recursion Pharmaceuticals (RXRX) Enterprise Value (2020 - 2025)
Historic Enterprise Value for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$663.0 million.
- Recursion Pharmaceuticals' Enterprise Value fell 5446.62% to -$663.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$663.0 million, marking a year-over-year decrease of 5446.62%. This contributed to the annual value of -$597.4 million for FY2024, which is 5131.74% down from last year.
- Recursion Pharmaceuticals' Enterprise Value amounted to -$663.0 million in Q3 2025, which was down 5446.62% from -$528.2 million recorded in Q2 2025.
- In the past 5 years, Recursion Pharmaceuticals' Enterprise Value ranged from a high of -$219.1 million in Q1 2021 and a low of -$663.0 million during Q3 2025
- In the last 5 years, Recursion Pharmaceuticals' Enterprise Value had a median value of -$503.5 million in 2025 and averaged -$486.2 million.
- Per our database at Business Quant, Recursion Pharmaceuticals' Enterprise Value plummeted by 16975.08% in 2022 and then skyrocketed by 3687.06% in 2024.
- Recursion Pharmaceuticals' Enterprise Value (Quarter) stood at -$516.6 million in 2021, then decreased by 6.7% to -$551.2 million in 2022, then increased by 28.37% to -$394.8 million in 2023, then crashed by 51.32% to -$597.4 million in 2024, then dropped by 10.98% to -$663.0 million in 2025.
- Its Enterprise Value was -$663.0 million in Q3 2025, compared to -$528.2 million in Q2 2025 and -$503.5 million in Q1 2025.